Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BeOne Medicines Ltd.
百濟神州有限公司
(a corporation incorporated under the laws of Switzerland)
(Stock Code: 06160)

OVERSEAS REGULATORY ANNOUNCEMENT – FORM S-8

This announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached for the document which has been published by BeOne Medicines Ltd. on the website of the U.S. Securities and Exchange Commission on June 11, 2026 (U.S. Eastern Time).

By order of the Board
BeOne Medicines Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, June 12, 2026

As of the date of this announcement, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Felix J. Baker and Dr. Xiaodong Wang as Non-executive Directors, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp as Independent Non-executive Directors.

As filed with the Securities and Exchange Commission on June 11, 2026

Registration No. 333-

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

BEONE MEDICINES LTD.
(Exact name of registrant as specified in its charter)

Switzerland	**98-1209416**
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

c/o BeOne Medicines I GmbH
94 Aeschengraben 27
Basel 4051
Switzerland
(Address, including zip code, of Principal Executive Offices)

Fifth Amended and Restated 2016 Share Option and Incentive Plan
Sixth Amended and Restated 2018 Employee Share Purchase Plan
(Full title of the plan)

BeOne Medicines USA, Inc.
55 Cambridge Parkway
Suite 700W
Cambridge, MA 02142
(Name and address of agent for service)

(781) 801-1800
(Telephone number, including area code, of agent for service)

Copy to:
Chan Lee
Senior Vice President, General Counsel
c/o BeOne Medicines USA, Inc.
55 Cambridge Parkway
Suite 700W
Cambridge, MA 02142
(781) 801-1800

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☐
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

REGISTRATION OF ADDITIONAL SECURITIES PURSUANT TO GENERAL INSTRUCTION E

This Registration Statement on Form S-8 registers an additional 75,400,000 ordinary shares under BeOne Medicines Ltd.'s (the "Registrant") Fifth Amended and Restated 2016 Share Option and Incentive Plan (the "2016 Equity Plan"), approved by the Registrant's shareholders on June 11, 2026, representing an increase of 75,400,000 ordinary shares to the number of shares authorized under the Registrant's Fourth Amended and Restated 2016 Share Option and Incentive Plan. The additional shares are of the same class as other securities relating to the 2016 Equity Plan for which the Registrant's Registration Statements on Form S-8 (Registration Nos. 333-209410, 333-216885, 333-223319, 333-228786, 333-241697, 333-266639, and 333-279980) filed on February 5, 2016, as amended by the Post-Effective Amendment No. 1 thereto filed on May 27, 2025; March 22, 2017, as amended by the Post-Effective Amendment No. 1 thereto filed on May 27, 2025; February 28, 2018, as amended by the Post-Effective Amendment No. 1 thereto filed on May 27, 2025; December 13, 2018, as amended by the Post-Effective Amendment No. 1 thereto filed on May 27, 2025; August 6, 2020, as amended by the Post-Effective Amendment No. 1 thereto filed on May 27, 2025; August 8, 2022, as amended by the Post-Effective Amendment No. 1 thereto filed on May 27, 2025; and June 5, 2024, as amended by the Post-Effective Amendment No. 1 thereto filed on May 27, 2025, respectively, are effective. The information contained in those registration statements is hereby incorporated by reference pursuant to General Instruction E.

This Registration Statement on Form S-8 registers an additional 3,250,000 ordinary shares under the Registrant's Sixth Amended and Restated 2018 Employee Share Purchase Plan (the "2018 ESPP"), approved by the Registrant's shareholders on June 11, 2026, representing an increase of 3,250,000 ordinary shares to the number of shares authorized under the Registrant's Fifth Amended and Restated 2018 Employee Share Purchase Plan. The additional shares are of the same class as other securities relating to the 2018 ESPP for which the Registrant's Registration Statements on Form S-8 (Registration Nos. 333-225543, 333-228786, and 333-279980) filed on June 8, 2018, as amended by the Post-Effective Amendment No. 1 thereto filed on May 27, 2025; December 13, 2018, as amended by the Post-Effective Amendment No. 1 thereto filed on May 27, 2025; and June 5, 2024, as amended by the Post-Effective Amendment No. 1 thereto filed on May 27, 2025, respectively, are effective. The information contained in the registration statement is hereby incorporated by reference pursuant to General Instruction E.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

ITEM 8. Exhibits

See the Exhibit Index below for a list of exhibits filed as a part of, or incorporated by reference into, this Registration Statement, which Exhibit Index is incorporated herein by reference.

Exhibit No.	Exhibit Description	Filed/ Furnished Herewith	Incorporated by Reference Herein from Form or Schedule	Filing Date	SEC File/ Reg. Number
5.1	Opinion of Homburger AG regarding the issue of ordinary shares being registered.	X			
23.1	Consent of Ernst & Young LLP	X			
23.2	Consent of Homburger AG (included in Exhibit 5.1).	X			
24.1	Power of Attorney (included on the signature page).	X			
99.1†	Fifth Amended and Restated 2016 Share Option and Incentive Plan		8-K (Exhibit 10.1)	6/11/2026	001-37686
99.2†	Sixth Amended and Restated 2018 Employee Share Purchase Plan		8-K (Exhibit 10.2)	6/11/2026	001-37686
107	Filing Fee Table	X			

† Indicates a management contract or any compensatory plan, contract or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Basel, Switzerland, on June 11, 2026.

BEONE MEDICINES LTD.

By: /s/ JOHN V. OYLER
Name: John V. Oyler
Title: Chief Executive Officer and Chairman

POWER OF ATTORNEY

We, the undersigned directors, officers and/or authorized representative of BeOne Medicines Ltd., hereby severally constitute and appoint John V. Oyler, Aaron Rosenberg and Chan Lee, and each of them singly, our true and lawful attorneys, with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the registration statement on Form S-8 filed herewith, and any and all pre-effective and post-effective amendments to said registration statement, under the Securities Act of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of BeOne Medicines Ltd., and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ JOHN V. OYLER John V. Oyler	Chief Executive Officer and Chairman *(Principal Executive Officer)*	June 11, 2026
/s/ AARON ROSENBERG Aaron Rosenberg	Chief Financial Officer *(Principal Financial Officer)*	June 11, 2026
/s/ TITUS BALL Titus Ball	Chief Accounting Officer *(Principal Accounting Officer)*	June 11, 2026
/s/ FELIX J. BAKER Felix J. Baker	Director	June 11, 2026
/s/ OLIVIER BRANDICOURT Olivier Brandicourt	Director	June 11, 2026
/s/ MARGARET DUGAN Margaret Dugan	Director	June 11, 2026
/s/ ANTHONY C. HOOPER Anthony C. Hooper	Director	June 11, 2026
/s/ ELIZABETH F. MOONEY Elizabeth F. Mooney	Director	June 11, 2026
/s/ ALESSANDRO RIVA Alessandro Riva	Director	June 11, 2026
/s/ CHARLES L. SAWYERS Charles L. Sawyers	Director	June 11, 2026
/s/ SHALINI SHARP Shalini Sharp	Director	June 11, 2026
/s/ XIAODONG WANG Xiaodong Wang	Director	June 11, 2026
BeOne Medicines USA, Inc.		
By: /s/ CHAN LEE Name: Chan Lee Title: Senior Vice President, General Counsel	Authorized Representative in the United States	June 11, 2026

Exhibit 5.1

Homburger

BeOne Medicines Ltd.
c/o BeOne Medicines I GmbH
Aeschengraben 27
21st Floor
4051 Basel
Switzerland

Homburger AG
Prime Tower
Hardstrasse 201
CH-8005 Zürich

homburger.ch
+41 43 222 10 00

June 11, 2026

BeOne Medicines Ltd. / Form S-8

We have acted as Swiss counsel to BeOne Medicines Ltd., a company limited by shares pursuant to Article 620 *et seq*. of the Swiss Code of Obligations of March 30, 1911, as amended, incorporated under the laws of Switzerland (the **Company**), in connection with the Registration Statement on Form S-8 (the **Registration Statement**) to be filed with the United States Securities and Exchange Commission (the **Commission**) under the Securities Act of 1933, as amended (the **Act**), with respect to the registration of up to 78,650,000 of the Company's registered ordinary shares (*Namenaktien*), nominal value USD 0.0001 per share (the Company's registered ordinary shares (*Namenaktien*), nominal value USD 0.0001 per share, generally the **Shares**), consisting of:

— an additional 75,400,000 Shares that may be delivered under the Company's Fifth Amended and Restated 2016 Share Option and Incentive Plan (the **2016 Equity Plan**), as approved by the Company's shareholders at the Company's annual general meeting held on June 11, 2026 (the **AGM**); and

— an additional 3,250,000 Shares that may be delivered under the Company's Sixth Amended and Restated 2018 Employee Share Purchase Plan (the **2018 ESPP**, and collectively with the 2016 Equity Plan, the **Plans**), as approved by the Company's shareholders at the AGM.

As such counsel, we have been requested to give our opinion as to certain legal matters under Swiss law.

Capitalized terms used but not defined herein have the meanings assigned to such terms in the Documents (as defined below).

I. Basis of Opinion

This opinion is confined to and given on the basis of the laws of Switzerland in force at the date hereof. Such laws and the interpretation thereof are subject to change. This opinion is also confined to the matters stated herein and the Documents (as defined below), and is not to be read as extending, by implication or otherwise, to any other document referred to in any of the Documents or any other matter.

For purposes of this opinion, we have not conducted any due diligence or similar investigation as to factual circumstances that are or may be referred to in the Documents, and we express no opinion as to the accuracy of representations and warranties of facts set out in the Documents or the factual background assumed therein.

In this opinion, Swiss legal concepts are expressed in English terms and not in their original language. These concepts may not be identical to the concepts described by the same English terms as they exist under the laws of other jurisdictions.

For purposes of this opinion, we have only reviewed the following documents (collectively, the **Documents**):

1. An electronic copy of the minutes of the meeting of the Company's board of directors (the **Board**), dated April 16, 2026 (the **Board Resolutions**), including, among other things, (a) a resolution approving the amendment and the restatement of the Plans, (b) a resolution recommending that the Company's shareholders approve at the AGM the reservation of (i) an additional 75,400,000 Shares available for issuance under the 2016 Equity Plan and (ii) an additional 3,250,000 Shares available for sale under the 2018 ESPP, and (c) a resolution authorizing the filing of the Registration Statement with the Commission;

2. an electronic copy of the resolutions passed by the shareholders of the Company (the **Shareholder Resolutions**) at the AGM, as reflected in the minutes of such meeting, dated June 11, 2026, regarding, among other things, the approval by the Company's shareholders of the amendment and restatement of the Plans as proposed by the Board in the Board Resolutions;

3. an electronic copy of each Plan, as amended and effective June 11, 2026;

4. an electronic copy of a certified copy of the articles of association (*Statuten*) of the Company dated June 8, 2026 in their version dated April 28, 2025 (the **Articles**), including the capital band included in Article 4a of the Articles (the **Capital Band**) and the conditional share capital included in Article 4b of the Articles (the **Conditional Share Capital**);

5. an electronic copy of the organizational regulations (*Organisationsreglement*) of the Company as of May 27, 2025 (the **Organizational Regulations**); and

6. an electronic copy of a certified excerpt from the commercial register of the Canton of Basel-City, Switzerland (the **Commercial Register**), for the Company, dated June 8, 2026 (the **Commercial Register Excerpt**).

II. Assumptions

In rendering the opinion below, we have assumed the following:

1. all documents produced to us as originals are authentic and complete, and all documents produced to us as copies (including, without limitation, fax and electronic copies) conform to the original;

2. all documents produced to us as originals and the originals of all documents produced to us as copies were duly executed and certified, as applicable, by the individuals purported to have executed or certified, as the case may be, such documents, and any electronic signatures on any such document have been affixed thereto by the individual to whom such electronic signature belongs and such individual has saved and submitted such document as so electronically signed in such a manner so as to prevent removal or other alteration of such signature;

3. the filing of the Registration Statement with the Commission has been authorized by all necessary actions under all applicable laws other than Swiss law;

4. the Registration Statement will be duly filed by the Company;

5. all factual information contained in the Registration Statements is true and accurate;

6. (a) the Commercial Register Excerpt is correct, complete, and up-to-date as of the date hereof, and (b) the Articles and the Organizational Regulations are in full force and effect and have not been amended subsequent to the date set forth above;

7. the Board Resolutions and the Shareholder Resolutions (a) have been duly resolved and otherwise in the manner set forth therein, and (b) have not been rescinded or amended and is in full force and effect;

8. with respect to any issuance of new Shares by the Company after the date hereof, including by way of an ordinary increase in the Company's share capital, or based on the Capital Band or based on the Conditional Share Capital, (a) the issue price for any such new Shares will have been fully paid, (b) any such new Shares will have been duly authorized by the Board and, if required, the general meeting of shareholders of the Company, (c) any such new Shares, to the extent required under applicable Swiss law, will have been registered in the competent commercial register in Switzerland, and (d) all other requirements under Swiss law, the Articles and the Organizational Regulations in connection with the creation and issuance of any such new Shares, including, but not limited to, the payment in cash or by way of set-off of the issue price for such Shares, will have been complied with;

9. any Shares issued by way of an ordinary increase in the Company's share capital, or based on the Capital Band or based on the Conditional Share Capital will be listed on the NASDAQ Global Select Market via American Depositary Shares (**ADS**), the Hong Kong Stock Exchange Limited (**HKEx**) and the Science and Technology Innovation Board of the Shanghai Stock Exchange (**STAR Market**) in accordance with applicable laws and regulations; and

10. all authorizations, approvals, consents, licenses, exemptions and other requirements for the filing of the Registration Statement or for any other activities carried on in view of, or in connection with, the performance of the obligations expressed to be undertaken by the Company in the Registration Statement have been duly obtained and are and will remain in full force and effect, and any related conditions to which the parties thereto are subject have been satisfied.

III. Opinion

Based on the foregoing and subject to the qualifications set out below, we are of the opinion that:

1. The Company is a corporation (*Aktiengesellschaft*) duly incorporated and validly existing under the laws of Switzerland with all requisite corporate power and authority to perform and to conduct its business as described in the Articles.

2. (a) All Shares registered in the Commercial Register as of the date hereof and delivered by the Company pursuant to the terms of the Plans have been duly and validly issued, and (b) any new Shares to be issued by the Company and delivered pursuant to the terms of the Plans in accordance with their terms, if and when issued by the Company, will be validly issued, fully paid as to their nominal value, and non-assessable.

IV. Qualifications

1. The lawyers of our firm are members of the Zurich bar and do not hold themselves out to be experts in any laws other than the laws of Switzerland. Accordingly, we are opining herein as to Swiss law only, based on our independent professional judgment. We express no opinion regarding the applicability or effect of the laws of any other jurisdiction concerning the matters covered herein.

2. Under Swiss law, Shares issued based on the Conditional Share Capital cannot be paid-in by way of contribution in kind. Share issuances based on the Conditional Share Capital are limited to 462,292,769 new Shares and subject to the limitations set forth in the Conditional Share Capital.

3. The authority of the Board to issue Shares based on the Capital Band will expire on April 28, 2029 and is subject to the limitations set forth in the Capital Band.

4. The exercise of voting rights and rights related thereto with respect to any Shares is only permissible after registration in the Company's share register as a shareholder with voting rights in accordance with the provisions of, and subject to the limitations provided in, the Articles and Swiss law.

5. Any issuance of the Shares based on the Conditional Share Capital must be confirmed by the auditor of the Company, and amended Articles reflecting the issuance of Shares from Conditional Share Capital, together with said confirmation by the Company's auditor, must be filed with the competent commercial register no later than three months after the end of the Company's fiscal year.

6. We express no opinion as to any commercial, accounting, tax, auditing or other non-legal matters.

* * *

We have issued this opinion as of the date hereof and we assume no obligation to advise you of any changes in fact or in law that are made or brought to our attention hereafter.

We hereby consent to the filing of this opinion as an exhibit to the Amendment. In giving such consent, we neither hereby concede that we are within the category of persons whose consent is required under Section 7 of the Act, or the rules or regulations of the SEC thereunder, nor thereby admit that we are experts with respect to any part of the Registration Statement within the meaning of the term "expert" as used in the Act or the rules and regulations promulgated thereunder.

This opinion is governed by and shall be construed in accordance with the laws of Switzerland.

Sincerely yours,

/s/ HOMBURGER AG
HOMBURGER AG

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Fifth Amended and Restated 2016 Share Option and Incentive Plan and the Sixth Amended and Restated 2018 Employee Share Purchase Plan of BeOne Medicines Ltd. of our reports dated February 26, 2026, with respect to the consolidated financial statements of BeOne Medicines Ltd., and the financial statement schedule listed in Item 15, and the effectiveness of internal control over financial reporting of BeOne Medicines Ltd., included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts
June 11, 2026

Calculation of Filing Fee Tables

S-8

BeOne Medicines Ltd.

Table 1: Newly Registered Securities

	Security Type	Security Class Title	Fee Calculation Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
1	Equity	Ordinary Shares, par value $0.0001 per share	Other	75,400,000	$ 20.57	$ 1,550,978,000.00	0.0001381	$ 214,190.06
2	Equity	Ordinary Shares, par value $0.0001 per share	Other	3,250,000	$ 17.49	$ 56,842,500.00	0.0001381	$ 7,849.95
			Total Offering Amounts:			$ 1,607,820,500.00		$ 222,040.01
			Total Fee Offsets:					$ 0.00
			Net Fee Due:					$ 222,040.01

Offering Note

1

1(a) These shares may be represented by the Registrant's American Depositary Shares ("ADSs"). Each ADS represents 13 Ordinary Shares. ADSs issuable upon deposit of the Ordinary Shares registered hereby were registered pursuant to a separate Registration Statement on Form F-6, as amended (File No. 333-286725).

1(b) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional Ordinary Shares of the Registrant which become issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant's outstanding Ordinary Shares.

1(c) Represents an increase of 75,400,000 Ordinary Shares under the Registrant's Fifth Amended and Restated 2016 Share Option and Incentive Plan, effective June 11, 2026 (the "2016 Plan"). Ordinary Shares available for issuance under the 2016 Plan were previously registered on Registration Statements on Form S-8 filed with the Securities and Exchange Commission on February 5, 2016 (File No. 333-209410), as amended by Post-Effective Amendment No. 1 thereto filed on May 27, 2025, March 22, 2017 (File No. 333-216885), as amended by Post-Effective Amendment No. 1 thereto filed on May 27, 2025, February 28, 2018 (File No. 333-223319), as amended by Post-Effective Amendment No. 1 thereto filed on May 27, 2025, December 13, 2018 (File No. 333-228786), as amended by Post-Effective Amendment No. 1 thereto filed on May 27, 2025, August 6, 2020 (File No. 333-241697), as amended by Post-Effective Amendment No. 1 thereto filed on May 27, 2025, August 8, 2022 (File No. 333-266639), as amended by Post-Effective Amendment No. 1 thereto filed on May 27, 2025, and June 5, 2024 (File No. 333-279980), as amended by Post-Effective Amendment No. 1 thereto filed on May 27, 2025.

1(d) Estimated in accordance with Rule 457(c) and (h) under the Securities Act, solely for the purpose of calculating the registration fee on basis of $20.57, the average of the high and low prices of the Registrant's ADSs, as quoted on the Nasdaq Global Select Market on June 10, 2026.

2

2(a) These shares may be represented by ADSs. Each ADS represents 13 Ordinary Shares. ADSs issuable upon deposit of the Ordinary Shares registered hereby were registered pursuant to a separate Registration Statement on Form F-6, as amended (File No. 333-286725).

2(b) Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional Ordinary Shares of the Registrant which become issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant's outstanding Ordinary Shares.

2(c) Represents an increase of 3,250,000 Ordinary Shares under the Registrant's Sixth Amended and Restated 2018 Employee Share Purchase Plan, effective June 11, 2026 (the "2018 ESPP"). Ordinary Shares available for issuance under the 2018 ESPP were previously registered on Registration Statements on Form S-8 filed with the Securities and Exchange Commission on June 8, 2018 (File No. 333-225543), as amended by Post-Effective Amendment No. 1 thereto filed on May 27, 2025, December 13, 2018 (File No. 333-228786), as amended by Post-Effective Amendment No. 1 thereto filed on May 27, 2025, and June 5, 2024 (File No. 333-279980), as amended by Post-Effective Amendment No. 1 thereto filed on May 27, 2025.

2(d) Estimated in accordance with Rule 457(c) and (h) under the Securities Act, solely for the purpose of calculating the registration fee on basis of $17.49, which is 85% of the average of the high and low prices of the Registrant's ADSs, as quoted on the Nasdaq Global Select Market on June 10, 2026. Pursuant to the 2018 ESPP, shares are purchased at a price equal to 85% of the fair market value of our ordinary shares on either the first business day of the offering period or the last business day of the offering period, whichever is lower.

Table 2: Fee Offset Claims and Sources ☑Not Applicable

	Registrant or Filer Name	Form or Filing Type	File Number	Initial Filing Date	Filing Date	Fee Offset Claimed	Security Type Associated with Fee Offset Claimed	Security Title Associated with Fee Offset Claimed	Unsold Securities Associated with Fee Offset Claimed	Unsold Aggregate Offering Amount Associated with Fee Offset Claimed	Fee Paid with Fee Offset Source
						Rule 457(p)					
Fee Offset Claims											
Fee Offset Sources											